Artificial Intelligence Algorithm Qualification: A Quality by Design Approach to Apply Artificial Intelligence in Pharma

References

1. 1.↵
   1. Huang M.-H.,
   2. Rust R. T.

   Artificial Intelligence in Service. J. Serv. Res. 2018, 21 (2), 155–172.

   OpenUrl
2. 2.↵
   1. Penrose R.,
   2. Mermin N. D.

   The Emperor's New Mind: Concerning Computers, Minds, and the Laws of Physics. Am. J. Phys. 1990, 58 (12), 1214–1216.

   OpenUrl
3. 3.↵
   1. Naimat A.

   The New Artificial Intelligence Market. O’Reilly Media, Inc., 2016.
4. 4.↵
   1. Kaur N.,
   2. Sood S. K.

   Cognitive Decision Making in Smart Industry. Comput. Ind. 2015, 74, 151–161.

   OpenUrl
5. 5.↵
   Data Science: Opportunities to Transform Chemical Sciences and Engineering: Proceedings of a Workshop—In Brief. The National Academies Press: Washington, DC, 2018.
6. 6.↵
   1. Price W. N.

   Making Do in Making Drugs: Innovation Policy and Pharmaceutical Manufacturing. Boston College Law Review 2014, 55 (2).
7. 7.↵
   , Quality Guideline Q8(R2): Pharmaceutical Development, Step 4. ICH: Geneva, 2009.
8. 8.↵
   1. Herwig C.,
   2. Wölbeling C.,
   3. Zimmer T.

   A Holistic Approach to Production Control: From Industry 4.0 to Pharma 4.0. Pharm. Eng. 2017.
9. 9.↵
   , Quality Guideline Q9: Quality Risk Management, Step 4. ICH: Geneva, 2005.
10. 10.↵
    , ICH Topic Q2 (R1): Validation of Analytical Procedures: Text and Methodology. EMA: London, 1995.
11. 11.↵
    1. Peterson J. J.,
    2. Snee R. D.,
    3. McAllister P. R.,
    4. Schofield T. L.,
    5. Carella A. J.

    Statistics in Pharmaceutical Development and Manufacturing. J. Qual. Technol. 2009, 41 (2), 111–134.

    OpenUrl
12. 12.↵
    1. Zhang G.,
    2. Hu M. Y.,
    3. Patuwo B. E.,
    4. Indro D. C.

    Artificial Neural Networks in Bankruptcy Prediction: General Framework and Cross-Validation Analysis. Eur. J. Oper. Res. 1999, 116 (1), 16–32.

    OpenUrlCrossRefWeb of Science
13. 13.↵
    Review of Particle Physics. Phys. Rev. D 2018, 98 (3), 030001.
14. 14.↵
    1. Diamantidis N.,
    2. Karlis D.,
    3. Giakoumakis E.

    Unsupervised Stratification of Cross-Validation for Accuracy Estimation. Artif. Intell. 2000, 116 (1), 1–16.

    OpenUrl
15. 15.↵
    1. Hastie T.,
    2. Tibshirani R.,
    3. Friedman J.

    The Elements of Statistical Learning. Data Mining, Inference, and Prediction, 2nd ed.; Springer, 2008.
16. 16.↵
    1. Smith R.,
    2. Ventura D.,
    3. Prince J. T.

    Novel Algorithms and the Benefits of Comparative Validation. Bioinformatics 2013, 29 (12), 1583–1585.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Saurwein F.,
    2. Just N.,
    3. Latzer M.

    Governance of Algorithms: Options and limitations. Info 2015, 17 (6), 35–49.

    OpenUrl
18. 18.↵
    1. Chu L. P.

    Data Science for Modern Manufacturing. O’Reilly Media, Inc., 2016.
19. 19.↵
    1. Kent A.,
    2. Williams J.

    Encyclopedia of Computer Science and Technology: Volume 25—Supplement 10: Applications of Artificial Intelligence to Agriculture and Natural Resource Management to Transaction Machine Architectures; Kent A., Williams J., Eds.; Encyclopedia of Computer Science Series; Taylor & Francis, 1991.
20. 20.↵
    1. Chow T. S.

    Testing Software Design Modeled by Finite-State Machines. IEEE Trans. Softw. Eng. 1978, 4 (3), 178–187.

    OpenUrlCrossRef
21. 21.↵
    1. Gao J.,
    2. Tao C.,
    3. Jie D.,
    4. Lu S.

    What Is AI Software Testing? and Why. In 2019 IEEE International Conference on Service-Oriented System Engineering (SOSE), San Francisco East Bay, CA, April 4–9, 2019, 27–2709.
22. 22.↵
    , Good Practices for Data Management and Integrity in Regulated GMP/GDP Environments. PIC/S: Geneva, 2018.
23. 23.↵
    1. Witjas-Paalberends E. R.,
    2. van Laarhoven L. P. M.,
    3. van de Burgwal L. H. M.,
    4. Feilzer J.,
    5. de Swart J.,
    6. Claassen E.,
    7. Jansen W. T. M.

    Challenges and Best Practices for Big Data-Driven Healthcare Innovations Conducted by Profit–Non-Profit Partnerships—A Quantitative Prioritization. Int. J. Healthc. Manag. 2018, 11 (3), 171–181.

    OpenUrl
24. 24.↵
    1. Barlow M.

    Artificial Intelligence Across Industries; O’Reilly Media, 2017.
25. 25.↵
    , Annex 5: Guidance on Good Data and Record Management Practices. WHO, 2016.
26. 26.↵
    , ‘GXP' Data Integrity Guidance and Definitions, Rev. 1. MHRA: London, 2018.
27. 27.↵
    , European Pharmacopoeia (Ph. Eur.), 9th edition, Council of Europe: Strasbourg, France, 2017.
28. 28.↵
    1. Menzies T.

    Verification and Validation and Artificial Intelligence. Foundations Johns Hopkins U. Applied Physics Lab Laurel 2002, 02.
29. 29.↵
    , Proposed Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD)—Discussion Paper and Request for Feedback. FDA, 2019.
30. 30.↵
    , HMA-EMA Joint Big Data Taskforce. Summary Report; EMA/105321/2019. EMA: London, 2019.
31. 31.↵
    1. Guinée J. B.,
    2. Lindeijer E.

    Handbook on Life Cycle Assessment: Operational Guide to the ISO Standards; Guinée J. B., Lindeijer E., Eds.; Eco-Efficiency in Industry and Science Vol. 7; Springer Science & Business Media, 2002.
32. 32.↵
    1. Muteki K.,
    2. Swaminathan V.,
    3. Sekulic S. S.,
    4. Reid G. L.

    De-Risking Pharmaceutical Tablet Manufacture through Process Understanding, Latent Variable Modeling, and Optimization Technologies. AAPS PharmSciTech 2011, 12 (4), 1324–1334.

    OpenUrlPubMed
33. 33.↵
    1. Lourenço V.,
    2. Lochmann D.,
    3. Reich G.,
    4. Menezes J. C.,
    5. Herdling T.,
    6. Schewitz J.

    A Quality by Design Study Applied to an Industrial Pharmaceutical Fluid Bed Granulation. Eur. J. Pharm. Biopharm. 2012, 81 (2), 438–447.

    OpenUrlPubMed
34. 34.↵
    1. Frankish K.,
    2. Ramsey W. M.

    The Cambridge Handbook of Artificial Intelligence; Frankish K., Ramsey W. M., Eds.; Cambridge University Press, 2014.
35. 35.↵
    1. Moor J.

    Workshop Report 4. The Dartmouth College Artificial Intelligence Conference: The Next Fifty Years. AAAI, 2006.
36. 36.↵
    1. Markarian J.

    Modernizing Pharma Manufacturing. Pharm Technol. 2018, 42 (4), 20–25.

    OpenUrl
37. 37.↵
    1. Mockute R.,
    2. Desai S.,
    3. Perera S.,
    4. Assuncao B.,
    5. Danysz K.,
    6. Tetarenko N.,
    7. Gaddam D.,
    8. Abatemarco D.,
    9. Widdowson M.,
    10. Beauchamp S.,
    11. Cicerello S.,
    12. Mingle E.

    Artificial Intelligence within Pharmacovigilance: A Means to Identify Cognitive Services and the Framework for Their Validation. Pharm. Med. 2019, 33 (2), 109–120.

    OpenUrl
38. 38.↵
    Case study: Artificial Intelligence and Machine Learning: Revolutionising Drug Development; IMED Annual Review, 2017.
39. 39.↵
    1. Ferreira A. P.,
    2. Tobyn M.

    Multivariate Analysis in the Pharmaceutical Industry: Enabling Process Understanding and Improvement in the PAT and QbD Era. Pharm. Dev.Technol. 2015, 20 (5), 513–527.

    OpenUrl
40. 40.↵
    Analysis Techniques for System Reliability—Procedures for Failure Mode and Effects Analysis (FMEA); IEC 60812:2006(E); IEC: Geneva, 2006.
41. 41.↵
    , USP 29—NF 24, USP: Rockville, MD, 2006.
42. 42.↵
    1. McCarthy J.

    What is Artificial Intelligence? 2007. Formal Reasoning Group of Stanford University Web site. http://www-formal.stanford.edu/jmc/whatisai/ (accessed February 3, 2020).
43. 43.↵
    , Quality Guideline Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management, Step 2. ICH: Geneva, 2017.
44. 44.↵
    1. Rowley A.,
    2. Turpin R.,
    3. Walton S.

    The Emergence of Artificial Intelligence and Machine Learning Algorithms in Healthcare: Recommendations to Support Governance and Regulation. Position paper, BSI, 2019.
45. 45.↵
    1. Norton M.,
    2. Karczub D.

    Fundamentals of Noise and Vibration Analysis for Engineers; Cambridge University Press, 2003.
46. 46.↵
    1. Liu F. T.,
    2. Ting K. M.,
    3. Zhou Z.-H.

    Isolation Forest. In 2008 Eighth IEEE International Conference on Data Mining, Pisa, Italy, December 15–19, 2008; IEEE, 2008; 413–422.